Floatz logo

Ruxolitinib

Adult T-cell Leukemia/Lymphoma

Jonathan BrammerSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

37 Active assets in the Adult T-cell Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
John Reneau
Phase 2BBB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 2BBB
Cyclophosphamide
John Reneau
Phase 4BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BBB
cc-5013
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
70 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →